Secukinumab treatment and vaccination efficacy

descriptionPublicationkeyboard_double_arrow_right Article 01 Apr 2022 English Publisher:Oxford University Press (OUP)Journal:Clinical and Experimental Dermatology, volume 47, pages 750-751 (issn: 0307-6938, eissn: 1365-2230,

Copyright policy )

Authors: A. Mohammed; R. Singh; S. R. Feldman;

doi: 10.1111/ced.15004

pmid: 34747527

Secukinumab treatment and vaccination efficacy

- Summary
- Subjects
- Metrics

Abstract

Dear Editor, Secukinumab, a monoclonal antibody against interleukin (IL)-17A, is used to treat psoriasis and psoriatic arthritis. The effect of this treatment on COVID-19 vaccination is not well characterized. While IL-17 deficiency states are associated with mucocutaneous infection with Candida albicans, there is no apparent increased risk of viral infection, and redundancy between IL-17A and IL-17F limits the impact of IL-17A deficiency on immune responsiveness.

Related Organizations

Dermatology Research Center
United States
Wake Forest University
United States

Keywords

Treatment Outcome, Double-Blind Method, Vaccination, Humans, Psoriasis, Antibodies, Monoclonal, Humanized, Severity of Illness Index

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	1
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average